pembrolizumab,rivoceranib,lenvatinib,tislelizumab,camrelizumab,sorafenib
jiangsu hengrui pharmaceuticals,elevar therapeutics,merck,beigene,eisai,bayer,novartis
['rationale301', 'hcc', 'leap002', 'apatinib', 'camrelizumab']
what a session! a packed room for three first-line phase 3 trials of #immunotherapy for #hcc #leap002 #rationale301 and #camrelizumabapatinib at #esmo22 #katiekelley #richardfinn 
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma